Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Recipharm AB (publ)    RECI B   SE0005757267

RECIPHARM AB (PUBL)

(RECI B)
My previous session
Most popular
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsOfficial PublicationsSector newsAnalyst Recommendations

Recipharm publ : appoints new Director of Business Management

share with twitter share with LinkedIn share with facebook
share via e-mail
0
02/12/2019 | 04:01am EST

Recipharm, the contract development and manufacturing organisation (CDMO), has appointed a new director of business management for the USA and Canada to accelerate growth in the region.

With over 8 years of experience working in the North American CDMO industry, Kieran Chouhan joins the business management team at Recipharm to lead sales activity in North America.

In his new role, Kieran will be responsible for sales and business development for the CDMO's commercial manufacturing services.

Kenth Berg, Vice President Business Management said: "We are thrilled to welcome Kieran to the Recipharm team to help drive sales and business development activity in North America. We are fully committed to achieving our goals there by offering first class development and manufacturing services. I am certain Kieran's experience will be an asset to the team throughout that journey."

Having established an extensive network of customers and secured substantial projects in North America, Kieran's wealth of experience and market knowledge will support Recipharm's growth ambitions in the US market.

Kieran said: "Recipharm's knowledge and end-to-end offering means it can cater for customised and challenging projects, which will be a great asset in the North American market in the coming years. I'm delighted to be joining the team in its quest for growth and global expansion."

Contact information
Kenth Berg, Vice President Business Management, kenth.berg@recipharm.com, +46 8 6025 216

For media enquiries, please contact Kate Hindhaugh at ramarketing: kate@ramarketingpr.com, + 44 (0)191 222 1242, www.ramarketingpr.com, Twitter: @ramarketingpr, Facebook: /ramarketingpr, LinkedIn: /ramarketing

About Recipharm
Recipharm is a leading Contract Development and Manufacturing Organisation (CDMO) in the pharmaceutical industry employing around 6,000 employees. Recipharm offers manufacturing services of pharmaceuticals in various dosage forms, production of clinical trial material and APIs, and pharmaceutical product development. Recipharm manufactures several hundred different products to customers ranging from big pharma to smaller research and development companies. Recipharm's turnover is approximately SEK 6.0 billion and the company operates development and manufacturing facilities in France, Germany, India, Israel, Italy, Portugal, Spain, Sweden, the UK and the US and is headquartered in Stockholm, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq Stockholm.
For more information on Recipharm and our services, please visit www.recipharm.com 

Recipharm AB (publ)
Corporate identity number 556498-8425
Address Box 603, SE-101 32 Stockholm, Sweden, Telephone +46 8 602 52 00
www.recipharm.com

http://news.cision.com/recipharm-ab/r/recipharm-appoints-new-director-of-business-management,c2738923

https://mb.cision.com/Main/9273/2738923/989497.pdf

(c) 2019 Cision. All rights reserved., source Press Releases - English

share with twitter share with LinkedIn share with facebook
share via e-mail
0
Latest news on RECIPHARM AB (PUBL)
02/14RECIPHARM PUBL : announces all its facilities are ready for EU serialisation
AQ
02/12RECIPHARM PUBL : appoints new Director of Business Management
AQ
2018RECIPHARM PUBL : explores ending operations in Ashton-under-Lyne facility
AQ
2018RECIPHARM PUBL : to potentially end operations in Ashton-under-Lyne facility
AQ
2018RECIPHARM PUBL : OnDosis and Recipharm partner to advance a novel treatment regi..
AQ
2018RECIPHARM PUBL : Recipharms proprietary molecule Erdosteine recognised as COPD t..
AQ
2018RECIPHARM PUBL : proprietary molecule Erdosteine recognised as COPD treatment
PU
2018RECIPHARM PUBL : proprietary molecule Erdosteine recognised as COPD treatment
AQ
2018RECIPHARM PUBL : CEO sells shares - remains committed and significant holder
AQ
2018RECIPHARM AB : publishes its interim report January - September 2018
AQ
More news
Financials (SEK)
Sales 2018 6 442 M
EBIT 2018 545 M
Net income 2018 227 M
Debt 2018 3 327 M
Yield 2018 0,87%
P/E ratio 2018 36,05
P/E ratio 2019 25,47
EV / Sales 2018 1,55x
EV / Sales 2019 1,30x
Capitalization 6 638 M
Chart RECIPHARM AB (PUBL)
Duration : Period :
Recipharm AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends RECIPHARM AB (PUBL)
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 171  SEK
Spread / Average Target 34%
EPS Revisions
Managers
NameTitle
Thomas Bengt Eldered President, Chief Executive Officer, MD & Director
Lars Rickard Backsell Chairman
Tobias Hägglöv Chief Financial Officer
Carl-Johan Spak Executive Vice President-Global Technologies
Per Anders Gustav Carlberg Independent Director
Sector and Competitors
1st jan.Capitalization (M$)
RECIPHARM AB (PUBL)10.07%715
ABBVIE-12.30%121 616
MERCK KGAA7.71%14 147
KYOWA HAKKO KIRIN CO LTD5.23%11 129
ZHANGZHOU PIENTZEHUANG PHARMACEUTICL LTD13.36%8 757
JAZZ PHARMACEUTICALS PLC1.10%7 596